Your browser doesn't support javascript.
loading
Circulating extracellular vesicle-encapsulated microRNA-557 induces a proinflammatory immune response and serves as a diagnostic or relapse marker in autoimmune hepatitis.
Abe, Kazumichi; Suzuki, Rei; Fujita, Masashi; Hayashi, Manabu; Takahashi, Atsushi; Ohira, Hiromasa.
Afiliación
  • Abe K; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Suzuki R; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Fujita M; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Hayashi M; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Takahashi A; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Ohira H; Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hepatol Res ; 52(12): 1034-1049, 2022 Dec.
Article en En | MEDLINE | ID: mdl-35962993
AIM: This study investigated serum microRNAs (miRNAs/miRs) in autoimmune hepatitis (AIH) and the relationship of these molecules with diagnostic and relapse markers. METHODS: Initially, extracellular vesicle-encapsulated miRNAs (EV-miRNAs) in serum with altered expression in AIH relative to healthy control (HC) samples were identified using microarray analysis. To validate the microarray results, the expression levels of selected EV-miRNAs were determined. RESULTS: Among the 2569 mature miRNAs evaluated in the microarray, EV-miR-557 discriminated patients with AIH from healthy controls (HCs). Validation by digital polymerase chain reaction indicated that serum EV-miR-557 levels were higher in patients with AIH (7.75 copies/µl) than in patients with non-alcoholic steatohepatitis (1.60 copies/µl; p < 0.001), patients with primary biliary cholangitis (2.16 copies/µl; p < 0.005), and HCs (1.86 copies/µl; p < 0.005). The area under the receiver operating characteristic curve values for the probability of AIH using serum EV-miR-557 between the AIH and non-alcoholic steatohepatitis, AIH and primary biliary cholangitis, and AIH and HC groups were 0.81, 0.78, and 0.79, respectively. In addition, serum EV-miR-557 levels >7.69 copies/µl were associated with a significantly higher risk of relapse in patients with AIH (7-year incidence rate: 11.1 vs. 35.4%, log-rank test, p < 0.05). Interestingly, gene expression analysis revealed that increased miR-557 expression following transient transfection of peripheral blood mononuclear cells with a miR-557 mimic resulted in enhanced expression of proinflammatory cytokine-related genes such as interleukin-6, interferon-γ, and tumor necrosis factor. Moreover, miR-557 induced significant tumor necrosis factor-α production (mean: 313.5 vs. 10 642.3 pg/ml, p < 0.05). CONCLUSION: EV-miR-557 may play an important role as a potential biomarker of AIH and may be a promising therapeutic target for AIH.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Hepatol Res Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Hepatol Res Año: 2022 Tipo del documento: Article País de afiliación: Japón